Evidence map›Paper›PMID 33407852›Full record

ArticleClinical epigenetics2021

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.

Johannes Lorenz Berg, Bianca Perfler, Stefan Hatzl, Marie-Christina Mayer, Sonja Wurm, Barbara Uhl, Andreas Reinisch, Ingeborg Klymiuk, Sascha Tierling, Gudrun Pregartner and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

Johannes Lorenz BergDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Bianca PerflerDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Stefan HatzlDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Marie-Christina MayerDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Sonja WurmDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Barbara UhlDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Andreas ReinischDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Ingeborg KlymiukCore Facility Molecular Biology, Medical University of Graz, Graz, Austria.
Sascha TierlingDepartment of Genetics, University of Saarland, Saarbrücken, Germany.
Gudrun PregartnerInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Gerhard BachmaierInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Andrea BergholdInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Klaus Geissler5th Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria.
Martin PichlerDivision of Oncology, Medical University of Graz, Graz, Austria.
Gerald HoeflerDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Herbert StroblOtto Loewi Research Centre, Immunology and Pathophysiology, Medical University of Graz, Graz, Austria.
Albert WölflerDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Heinz SillDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria.
Armin ZebischDivision of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria. armin.zebisch@medunigraz.at.ORCID 0000-0002-4861-7021
Medical University of Graz · ATSaarland University · DESigmund Freud Privatuniversität Wien · ATThe University of Texas MD Anderson Cancer Center · US

Funding

Austrian Science Fund FWF P 32783
6 · The paper itself

Abstract

backgroundChronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic malignancy that arises from hematopoietic stem and progenitor cells (HSPCs). Patients with CMML are frequently treated with epigenetic therapeutic approaches, in particular the hypomethylating agents (HMAs), azacitidine (Aza) and decitabine (Dec). Although HMAs are believed to mediate their efficacy via re-expression of hypermethylated tumor suppressors, knowledge about relevant HMA targets is scarce. As silencing of tumor-suppressive micro-RNAs (miRs) by promoter hypermethylation is a crucial step in malignant transformation, we asked for a role of miRs in HMA efficacy in CMML.

resultsInitially, we performed genome-wide miR-expression profiling in a Kras

conclusionsTaken together, we report decreased expression of miR-125a in CMML and delineate its relevance as mediator of HMA efficacy within this neoplasia.

Indexed as

RNA, MessengerAnimalsAntimetabolites, AntineoplasticAzacitidineDecitabineDisease Models, AnimalDNA MethylationGene Expression RegulationGenome-Wide Association StudyHumansLeukemia, Myelomonocytic, ChronicMiceAntimetabolites, AntineoplasticAzacitidineDecitabineRNA, MessengerAzacitidineChronic myelomonocytic leukemiaHypomethylating agentmiRNATumor suppressor

Identifiers

PMID33407852
PMCPMC7789782
OpenAlexW3120060195

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.